Optispan Success Story: What 18 Months of Real Biomarker Data Actually Looks Like (With Carlos Pinto)

<p>What does over 18 months of precision medicine actually look like in practice? In this episode of the Optispan Success Story Series, Dr. Matt Kaeberlein sits down with Carlos Pinto, a tech executive and early Optispan client, to trace his longitudinal health journey from metabolic warning signs to measurable, sustained transformation. Carlos shares how a decade of overlooked biomarkers, a post-pandemic health decline, and a single panic attack became the catalyst for a data-driven approach to his own biology. Together, he and Dr. Kaeberlein review real DEXA, lipid, metabolic, and environmental biomarker data, unpacking what moved the needle, what didn&#39;t, and why the answer was rarely simple. This conversation is a candid look at what it means to become your own best health advocate, not through quick fixes, but through personalized, longitudinal learning.<strong>Timestamps:</strong>0:00 – Cold open &amp; highlights0:50 – Welcome &amp; Carlos&#39;s background in tech leadership2:15 – How career ambition displaced health in his 20s and 30s3:39 – A panic attack as the turning point: connecting mental and physical health4:24 – A previous medical wellness program: what worked and what was missing6:34 – Arriving at OptiSpan: intention, mindset, and expectations7:15 – Gateway Day: comprehensive baseline testing and initial surprises8:51 – Early metabolic lessons: CGM data, glucose spikes, and dawn effect11:32 – Confronting white coat hypertension with 78 data points13:28 – How stress, sleep, and nutrition interact to drive metabolic dysfunction15:44 – Personal experimentation as methodology: berberine, time-restricted eating, and fish17:09 – Mercury toxicity from fish consumption: a case study in biomarker surveillance18:33 – Stress management protocols: walking, meditation, and measurable outcomes19:49 – Statin introduction: the role of medication as a tool, not a failure20:27 – DEXA results: visceral fat reduction, body fat loss, and lean mass gain24:17 – Lipid profile transformation: ApoB from ~115 to 70, LDL from 160 to 7425:57 – A1C trajectory and the complexity of glucose optimization30:01 – Reframing medication: proactive use vs. reactive disease management31:29 – Mercury biomarker deep dive: from 2.4 to 16 and back to 232:21 – Goals for the future: sustainability, muscle retention, and mental clarity36:30 – Lineage biological age algorithm: from mortality risk of 54 to 5239:27 – Closing reflections: health as a lifelong trajectory, not a program</p>